Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCE-MRI assessment of bevacizumab with or without interferon alfa-2a in advanced renal cell carcinoma
ISRCTN08193901Phase 2Completed
- Sponsor
- East and North Hertfordshire NHS Trust
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of bevacizumab and interferon alfa-2a in renal cell carcinoma (RCC) (3 arms), sponsored by East and North Hertfordshire NHS Trust. Started Apr 2009; status: completed.
02
Drugs
bevacizumabinterferon alfa-2a
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ISRCTN08193901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN08193901.